Human Serum Albumin and Human Serum Albumin Nanoparticles As Carriers of 10-(2'-Pyrimidyl)-3,6-diazaphenothiazine: In Vitro Spectroscopic Studies

Overview

Journal Molecules

Publisher MDPI

Date 2025 Jan 25

PMID 39860185

Authors

Aleksandra Owczarzy

Karolina Kulig

Beata Morak-Mlodawska

Malgorzata Jelen

Tammam Muhammetoglu

Wojciech Rogoz

Malgorzata Maciazek-Jurczyk

Affiliations

Soon will be listed here.

Abstract

Human serum albumin (HSA) plays a fundamental role in the human body, including the transport of exogenous and endogenous substances. HSA is also a biopolymer with a great medical and pharmaceutical potential. Due to nontoxicity and biocompatibility, this protein can be used as a nanocarrier. 10-(2'-Pyrimidyl)-3,6-diazaphenothiazine (10-Pyr-3,6-DAPT) is a phenothiazine showing high anticancer potential in vitro against glioma, melanoma and breast cancer cells. Additionally, this compound is characterized by selectivity of action towards MCF-7 breast cancer and has low cytotoxicity towards normal cells. Considering the promising pharmacological potential of this compound and using spectroscopic techniques, HSA and human serum albumin nanoparticles (HSA-NP) were tested as carriers of this molecule. Based on the obtained data and the appropriate mathematical models (Stern-Volmer and Klotz models), it can be concluded that 10-Pyr-3,6-DAPT probably forms a weak (K = (5.24 ± 0.57) × 10 and K = (4.67 ± 0.59) × 10) for excitation wavelengths λ 275 nm and λ 295 nm, respectively) static complex (k > 10) with HSA (at Sudlow site II (subdomain IIIA), and the phenomenon of it having both strong therapeutic and toxic effects is possible. High encapsulation efficiency of 10-Pyr-3,6-DAPT into the HSA-NPs was obtained, and the changes in albumin secondary structure due to the presence of 10-Pyr-3,6-DAPT were registered. Based on the data presented, it can be concluded that due to the high toxic effects of 10-Pyr-3,6-DAPT, a better carrier may be HSA-NPs.

References

Teran-Saavedra N, Sarabia-Sainz J, Velazquez-Contreras E, Ramos-Clamont Montfort G, Pedroza-Montero M, Vazquez-Moreno L . Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin. Molecules. 2020; 25(22). PMC: 7699757. DOI: 10.3390/molecules25225432. View

Tasciotti E, Liu X, Bhavane R, Plant K, Leonard A, Price B . Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol. 2008; 3(3):151-7. DOI: 10.1038/nnano.2008.34. View

Maciazek-Jurczyk M, Janas K, Pozycka J, Szkudlarek A, Rogoz W, Owczarzy A . Human Serum Albumin Aggregation/Fibrillation and its Abilities to Drugs Binding. Molecules. 2020; 25(3). PMC: 7038104. DOI: 10.3390/molecules25030618. View

KLOTZ I, Hunston D . Properties of graphical representations of multiple classes of binding sites. Biochemistry. 1971; 10(16):3065-9. DOI: 10.1021/bi00792a013. View

Owczarzy A, Trzepacz M, Kulig K, Rogoz W, Zieba A, Maciazek-Jurczyk M . In vitro spectroscopic studies of 9-amino-5-alkyl-12(H)-quino[3,4-b][1,4]benzothiazine chloride with main carrier plasma proteins. Chem Biol Interact. 2024; 405:111289. DOI: 10.1016/j.cbi.2024.111289. View

Bteich M . An overview of albumin and alpha-1-acid glycoprotein main characteristics: highlighting the roles of amino acids in binding kinetics and molecular interactions. Heliyon. 2019; 5(11):e02879. PMC: 6895661. DOI: 10.1016/j.heliyon.2019.e02879. View

Zhang J, Ming C, Zhang W, Okechukwu P, Morak-Mlodawska B, Pluta K . 10-3,6-Diazaphenothiazine induces G/M phase cell cycle arrest and caspase-dependent apoptosis and inhibits cell invasion of A2780 ovarian carcinoma cells through the regulation of NF-κB and (BIRC6-XIAP) complexes. Drug Des Devel Ther. 2017; 11:3045-3063. PMC: 5661483. DOI: 10.2147/DDDT.S144415. View

Sudlow G, Birkett D, Wade D . Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol. 1976; 12(6):1052-61. View

Vukic M, Vukovic N, Obradovic A, Matic M, Djukic M, Avdovic E . Redox status, DNA and HSA binding study of naturally occurring naphthoquinone derivatives. EXCLI J. 2020; 19:48-70. PMC: 7003638. DOI: 10.17179/excli2019-1859. View

10.

Kelly S, Jess T, Price N . How to study proteins by circular dichroism. Biochim Biophys Acta. 2005; 1751(2):119-39. DOI: 10.1016/j.bbapap.2005.06.005. View

11.

Ciepluch K, Biehl R, Bryszewska M, Arabski M . Poly(propylene imine) dendrimers can bind to PEGylated albumin at PEG and albumin surface: Biophysical examination of a PEGylated platform to transport cationic dendritic nanoparticles. Biopolymers. 2020; 111(9):e23386. DOI: 10.1002/bip.23386. View

12.

Agudelo D, Bourassa P, Bruneau J, Berube G, Asselin E, Tajmir-Riahi H . Probing the binding sites of antibiotic drugs doxorubicin and N-(trifluoroacetyl) doxorubicin with human and bovine serum albumins. PLoS One. 2012; 7(8):e43814. PMC: 3427208. DOI: 10.1371/journal.pone.0043814. View

13.

Fanali G, Di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P . Human serum albumin: from bench to bedside. Mol Aspects Med. 2012; 33(3):209-90. DOI: 10.1016/j.mam.2011.12.002. View

14.

Ryan A, Ghuman J, Zunszain P, Chung C, Curry S . Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin. J Struct Biol. 2010; 174(1):84-91. PMC: 3073228. DOI: 10.1016/j.jsb.2010.10.004. View

15.

Owczarzy A, Rogoz W, Kulig K, Pozycka J, Zieba A, Maciazek-Jurczyk M . Spectroscopic Studies of Quinobenzothiazine Derivative in Terms of the In Vitro Interaction with Selected Human Plasma Proteins: Part 2. Molecules. 2023; 28(2). PMC: 9865466. DOI: 10.3390/molecules28020698. View

16.

Bojko B, Vuckovic D, Pawliszyn J . Comparison of solid phase microextraction versus spectroscopic techniques for binding studies of carbamazepine. J Pharm Biomed Anal. 2012; 66:91-9. DOI: 10.1016/j.jpba.2012.03.005. View

17.

Owczarzy A, Zieba A, Pozycka J, Kulig K, Rogoz W, Szkudlarek A . Spectroscopic Studies of Quinobenzothiazine Derivative in Terms of the In Vitro Interaction with Selected Human Plasma Proteins. Part 1. Molecules. 2021; 26(16). PMC: 8401767. DOI: 10.3390/molecules26164776. View

18.

Maciazek-Jurczyk M . Phenylbutazone and ketoprofen binding to serum albumin. Fluorescence study. Pharmacol Rep. 2014; 66(5):727-31. DOI: 10.1016/j.pharep.2014.03.005. View

19.

Weber C, Coester C, Kreuter J, Langer K . Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm. 1999; 194(1):91-102. DOI: 10.1016/s0378-5173(99)00370-1. View

20.

Kulig K, Denisiuk Z, Klosek M, Owczarzy A, Rogoz W, Sedek L . Circular Dichroism as a Rapid Method for Analyzing the Binding of a Targeting Ligand to the Surface of Albumin Nanoparticles. Pharmaceuticals (Basel). 2023; 16(10). PMC: 10609751. DOI: 10.3390/ph16101423. View